US Patent

US10039718 — Use of solid carrier particles to improve the processability of a pharmaceutical agent

Formulation · Assigned to Gilead Sciences Inc · Expires 2032-10-06 · 6y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a composition that includes a compound used to inhibit cytochrome P-450, combined with solid carrier particles.

USPTO Abstract

The invention provides a composition comprising, a compound of formula (I): or a pharmaceutically acceptable salt thereof and a plurality of solid carrier particles, as well as methods for using the composition to inhibit the activity of cytochrome P-450.

Drugs covered by this patent

Patent Metadata

Patent number
US10039718
Jurisdiction
US
Classification
Formulation
Expires
2032-10-06
Drug substance claim
No
Drug product claim
Yes
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.